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Abstract
5-aminosalicylate (5-ASA) agents remain the mainstay 
treatment in ulcerative colitis (UC). A number of oral 
5-ASA agents are commercially available, including azo-
bond pro-drugs, as well as delayed- and controlled-
release forms of mesalazine. However, poor adherence 
due to frequent daily dosing and a large number of 
tablets has been shown to be an important barrier to 
successful management of patients with UC. Recently, 
new, once-daily formulations of mesalazine, including 
the unique multi-matrix delivery system and mesalazine 
granules, were proven to be efficacious in inducing and 
maintaining remission in mild-to-moderate UC, with 
a good safety profile comparable to that of other oral 
mesalazine formulations. In addition, they offer the 
advantage of a low pill burden and might contribute to 
increased long-term compliance and treatment success 
in clinical practice. This editorial summarizes the available 
literature on the short- and medium-term efficacy and 
safety of the new once-daily mesalazine formulations.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
The pathogenesis of  ulcerative colitis (UC) has only 
been partly elucidated. Inflammatory bowel disease 
(IBD) is a multifactorial entity with both genetic 
and environmental factors contributing to disease 
pathogenesis[1]. Worldwide, the incidence rates for UC 
vary from 0.5 to 24.5 per 100 000 person-years[2]. Recent 
reports from China and Korea also present an increase 
in patient numbers[3]. The classical presentation is that 
of  rectal bleeding and diarrhea, with other symptoms 
such as urgency, tenesmus, and abdominal cramping 
also being common. The disease might be limited to the 
rectum or extend proximally to include the entire colon 
and is characterized by a remission-relapse course in 
most patients.
5-aminosalicylic acid (5-ASA) remains the mainstay 
treatment in mild to moderate UC[4]. In left-sided and 
extensive cases, a combination of  oral and topical 
mesalazine appears to be more effective than either 
alone; however, this is probably not a simple dose-
response effect, as higher topical 5-ASA doses do not 
improve efficacy[5]. A number of  oral 5-ASA agents are 
commercially available, including azo-bond prodrugs, such 
as sulfasalazine, olsalazine and balsalazide, and delayed- 
and controlled-release forms of  mesalazine. Overall, 
the safety profile of  oral 5-ASA agents is favorable and 
similar to that of  a placebo in large clinical trials[6]. In 
addition, the use of  sulfasalazine is mainly limited by 
its side effects (including nausea, vomiting, abdominal 
pain, fever, skin rash, agranulocytosis, neutropenia, male 
infertility, folate deficiency, neuropathy, autoimmune 
hemolysis, and, rarely, nephrotoxicity, hepatotoxicity or 
pancreatitis) and the high rate of  intolerance (up to 20%). 
Somewhat in contrast, although mild side effects are more 
common with sulfasalazine, some of  the more severe 
side effects, for example pancreatitis, are more common 
with mesalazine (OR: 7.0), with intestinal nephritis being 
exclusively described for mesalazine[7]. Conclusions from 
this study, however, were criticized due to incomplete data 
collected through spontaneous reporting. Interestingly, 
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in a recent review by the Cochrane group, mesalazine 
was not superior compared to sulfasalazine for inducing 
response or remission (OR = 0.83, 95% CI: 0.60-1.13)[6], 
but was better tolerated.
Much emphasis has been placed on the manner in 
which different delivery systems may influence response 
to 5-ASAs; however, evidence in clinical practice for 
variability in efficacy is rather weak. Delivery systems 
can be divided into azo-compounds, controlled release, 
pH-dependent (either pH 6 or 7) and composite (pH-
dependent combined with controlled release)[8]. In 
addition, the effectiveness of  oral therapy relies on good 
compliance, which may be adversely affected by frequent 
daily dosing and a large number of  tablets. Recent studies 
have shown that poor adherence has been an important 
barrier to the successful management of  patients with 
UC. Only 40% to 60% of  the patients who are newly 
diagnosed or have longstanding disease are adherent 
to therapy[9,10]. Hence, once-daily oral formulations 
of  5-ASA are likely to be a better therapeutic option 
in clinical practice, partly due to improved adherence. 
Furthermore, when assessing remission and response 
rates, one must be aware that the placebo group rates 
may vary anywhere from 0 to 40% according to the 
definition used for response and remission. In a recent 
review[11], a significant heterogeneity was reported 
among studies using different criteria (e.g. UCDAI, 
Rachmilewitz). Thus, the direct comparison of  studies 
using different criteria is difficult to interpret.
A new, oral delayed-release formulation of  mesalazine 
utilizing Multi Matrix System (MMX) technology (hereafter 
referred to as MMX mesalazine) was recently approved in 
the US for the induction and maintenance of  remission in 
patients with active, mild-to-moderate ulcerative colitis[12]. 
It is a high dose (mesalazine 1.2 g/tablet), delayed-
release form that permits once-daily administration. The 
MMX technology involves incorporating mesalazine 
into a lipophilic matrix, which itself  is dispersed within 
a hydrophilic matrix, to delay and prolong dissolution. 
A gastro-resistant polymer film prevents initial drug 
release until exposed to a pH < 7, thus the film coat 
normally starts to dissolve only in the terminal ileum. The 
hydrophilic matrix is then exposed to intestinal fluids and 
swells, resulting in the formation of  a viscous gel mass 
with a slow and gradual release of  mesalazine throughout 
the length of  the colon. This editorial will focus on the 
efficacy and tolerability of  the new, once-daily mesalazine 
formulations.
EFFICACY AND SAFETY OF THE MMX 
MESALAZINE IN INDUCTION AND 
MAINTENANCE OF REMISSION
First, a preliminary randomized, double-blind, double-
dummy clinical study compared the efficacy of  MMX 
mesalazine versus topical mesalazine in 79 patients with 
active, left-sided, mild-to-moderate UC[13]. Comparable 
clinical remission rates were achieved; 60% of  the 
patients in the MMX mesalazine group and 50% of  the 
patients in the enema group were in clinical remission at 
the end of  week eight. Endoscopic remission rates were 
also not significantly different. Overall compliance was 
97% for oral administration and 87.5% for the enema. In 
a subsequent Phase Ⅱ, randomized, double-blind, dose-
ranging study, D’Haens et al[14] evaluated three different 
doses of  MMX mesalazine (1.2, 2.4, and 4.8 g/d) 
given once daily for the induction of  remission in 38 
patients with mild-to-moderate UC in an eight week 
trial. Remission at the end of  week eight was defined as 
a UC Disease Activity Index (UC-DAI) score of  1 or 
less, a score of  0 for rectal bleeding and stool frequency, 
and at least a 1-point reduction in sigmoidoscopy scores 
from baseline. Remission was achieved in 0% (0/12), 
30.8% (4/13), and 18% (2/11) of  the patients receiving 
MMX mesalazine 1.2, 2.4, and 4.8 g/d, respectively, 
with no statistically significant differences (P = 0.13). 
Improvements in physician’s global assessment (PGA), 
stool frequency, and rectal bleeding were similar in all 
treatment arms. 
The FDA’s approval of  MMX mesalazine (SPD476, 
MezavantTM, Lia ldaTM) was based on the two 
randomized, double-blind, placebo-controlled Phase 
Ⅲ trials[15,16]. The first trial investigated the efficacy of  
MMX mesalazine 1.2 g twice daily and 4.8 g once-daily 
compared with the placebo for eight weeks, for the 
induction of  remission in 280 patients with mild-to-
moderate UC. The primary endpoint was endoscopic 
and clinical remission at week eight, defined as a 
modified UC-DAI ≤ 1 with a subscore of  0 for rectal 
bleeding and stool frequency, a combined PGA and 
sigmoidoscopy score of  ≤ 1, a sigmoidoscopy score 
reduction of  ≥ 1 from baseline, and no mucosal 
friabil ity. Secondary endpoints included clinical 
improvement (reduction in modified UC-DAI scores 
from baseline of  ≥ 3 points) and clinical remission 
(scores of  0 for stool frequency and rectal bleeding). At 
the end of  week eight, both MMX mesalazine groups 
achieved statistically significant clinical and endoscopic 
remission compared with the placebo (34.1% and 29.2% 
vs 12.9%, 2.4 g/d and 4.8 g/d vs placebo, P < 0.001 
and P = 0.009, respectively). A statistically significant 
proportion of  patients receiving either dose of  MMX 
mesalazine achieved clinical improvement and clinical 
remission (37.5%, 32.6% vs 18.8%, P < 0.05) compared 
with the placebo. The median time to initial clinical 
remission (lasting ≥ three consecutive days) was 43 
and 44 d for the 2.4 g/d and 4.8 g/d MMX mesalazine 
groups, respectively; in contrast it was not reached for 
the placebo. 
In the second Phase Ⅲ double-blind, placebo-
controlled, multicenter clinical trial, Kamm et al [16] 
randomized 343 patients with active, mild-to-moderate 
UC to receive MMX mesalazine 2.4 g once daily, MMX 
mesalazine 4.8 g once daily, placebo, or a delayed-release 
mesalazine (AsacolTM) 800 mg, 3 times daily. The 
Asacol group served as a reference arm in the study. Due 
to the study’s double-dummy design, all patients received 
4 tablets and 2 capsules in the morning, 2 capsules at 
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lunch time, and 2 capsules in the evening. Significantly 
more patients achieved clinical and endoscopic remission 
at week eight in the MMX mesalazine groups compared 
with the placebo group (40.5% and 41.2% vs 22.1% with 
2.4 g/d, 4.8 g/d vs placebo; P = 0.01 and P = 0.007). In 
contrast, the Asacol group demonstrated only a trend 
for improvement (32.6% vs 22.1%; P = 0.124). MMX 
mesalazine was not directly compared with Asacol. 
Interestingly, endoscopic remission rates (69% for MMX 
2.4 g/d, 77.6% for MMX 4.8 g/d, 61.6% for Asacol, and 
46.5% for the placebo) exceeded clinical remission rates 
for both active treatment and placebo groups and were 
much better than previously reported for 5-ASA. 
In a combined analysis[17] of  the two trials, data from 
517 patients were analyzed. Eight-week remission rates 
were 37.2% and 35.1% in the MMX mesalazine 2.4 g⁄d 
and 4.8 g⁄d groups, respectively, versus 17.5% in the 
placebo group (P < 0.001, for both). The respective rates 
for clinical improvement were 58%, 62%, and 33%. The 
eight-week, complete mucosal healing rates were 32% 
in both MMX mesalazine groups compared with 16% 
in the placebo group. In an intent-to-treat analysis, the 
median time to resolution of  symptoms (stool frequency 
and rectal bleeding) was 25, 26, and 44 d, respectively[18]. 
The median time to resolution of  rectal bleeding 
was seven, eight, and 16 d, while the median time to 
normalization of  stool frequency was 19, 20, and 34 d. 
In a subsequent analysis[19], the authors stratified 
the data according to disease extent, severity, gender 
and prior 5-ASA use. The percentage of  patients in 
clinical and endoscopic remission was not different 
according to disease extent and severity and among 
patients who did not previously receive low-dose 5-ASA. 
Among patients transferring directly from prior low-
dose oral 5-aminosalicylic acid, MMX mesalazine 4.8 g
⁄d was significantly (P = 0.018) more effective than the 
placebo in inducing clinical and endoscopic remission. 
Efficacy over the placebo did not reach significance in 
patients transferring directly to MMX mesalazine 2.4 g/d. 
Interestingly, remission rates were higher in females in 
both active treatment groups and placebo groups (44.8% 
for MMX 2.4 g/d, 41.4% for MMX 4.8 g/d, and 20.7% 
for the placebo) compared to males (29.4%, 28.7%, and 
14.3%, P = 0.008). Nevertheless, in a logistic regression 
analysis, the authors excluded the gender effect. It is 
not clear, however, which other possible confounding 
variables were included in the analysis. 
If  patients were not in remission after an eight-week 
treatment with either MMX mesalazine 2.4 g once daily, 
MMX mesalazine 4.8 g once daily, placebo, or a delayed-
release mesalazine (AsacolTM) 800 mg 3-times-daily, 
patients were offered an open-label extension treatment 
with 4.8 g MMX mesalazine for another eight weeks[20]. 
Out of  the 304 patients who entered the extension 
study, 59.5% of  patients achieved remission at the end 
of  the extension treatment irrespective of  prior therapy. 
Normal mucosal appearance was seen at sigmoidoscopy 
in 42.4% of  the patients at the end of  the extension 
study vs 3.3% prior to the extension phase.
Upon completion of  the remission induction 
trials, eligible patients could enter a Phase Ⅲ open-
label extension study to evaluate the long-term efficacy 
and safety of  MMX mesalazine in the maintenance of  
remission. Patients who were not in remission at the end 
of  the original induction trial were offered an additional 
eight-week open label MMX mesalazine 4.8 g/d 
treatment administered twice daily[21]. Those who were in 
remission at either eight or 16 wk were then randomized 
to MMX mesalazine 2.4 g/d given once or twice daily 
for 12 mo. Two-hundred-twenty-five and 234 patients 
were randomized into the two treatment groups. At 
the end of  the 12-mo follow-up, 67.8% and 72.3% of  
the patients were strictly defined to have clinical and 
endoscopic remission in the per-protocol population. 
88.7% and 92.5% of  the patients were not considered 
to have relapsed based on the physician’s clinical 
assessment and the need for alternative therapy. These 
data are comparable to other mesalazine agents, with 
reported remission rates of  60%-70% after 6-12 mo of  
maintenance therapy[22].
 In a post-hoc analysis[23], the authors did not 
find differences in the relapse rate according to the initial 
treatment; relapse rates at 12 mo were 6.3%, 10.8%, and 
5.6% for patients initially treated with MMX mesalazine 
2.4 g/d, 4.8 g/d or Asacol 2.4 g/d, respectively. No 
significant differences were found in remission rates in a 
similar sub-group analysis in patients with baseline mild 
or moderate (71% vs 64%) and left-sided or extensive 
(67% vs 65%) ulcerative colitis. Similarly, relapse rates 
were independent of  previous relapse history, although 
there was a trend for increased frequency of  relapses 
in patients with a higher number of  prior relapses (< 
3 prior relapses: 70.1% vs ≥ 3 prior relapses: 59.8%). 
In contrast, the degree of  initial mucosal inflammation 
(mild: 68.6%, moderate: 68.1%, and severe: 43.3%) and 
time needed to induce remission (remission at week 
eight: 75.8% vs remission at week 16: 55.9%) were 
significantly associated with decreased remission rates at 
12 mo[21,24,25].
In a subsequent Italian multicenter study[26], the 
authors preliminary reported on the efficacy of  once-
daily 2.4 g MMX mesalazine vs 2.4 g delayed-release 
mesalazine (AsacolTM) maintenance therapy taken twice 
daily in 323 mild-to-moderate patients with left-sided 
ulcerative colitis in clinical remission without mucosal 
friability. At 12 mo, 30.8% vs 43.2% of  the patients 
relapsed in the two groups in a per-protocol analysis, 
resulting in an 11.3% difference in long-term remission 
rates in favor of  the once-daily treatment (95% CI: 
-0.01-22.7).
MMX mesalazine was generally well tolerated in 
all controlled clinical trials, with most adverse events 
being of  mild or moderate severity. Of  the 434 MMX 
mesalazine recipients evaluated for safety in the four 
published controlled trials[13-21], only two patients 
had serious adverse events that were considered 
treatment-related; both included pancreatitis caused 
by hypersensitivity to mesalazine. There was no 
evidence of  a dose-response relationship with MMX 
mesalazine for any tolerability parameter in either trial. 
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The most common treatment-related adverse events 
were headache, flatulence, and abdominal pain. Severe 
events were more common in the placebo recipients 
(6.1%) than in patients receiving MMX mesalazine 2.4 
or 4.8 g/d (1.1% and 2.2%), and mostly consisted of  
gastrointestinal events related to the underlying disease.
The eff icac ies of  the new MMX mesalaz ine 
formulations for the induction of  remission in mild-to-
moderate UC are summarized in Table 1.
THERAPEUTIC EFFICACY AND SAFETY 
OF OTHER ONCE-DAILY MESALAZINE 
FORMULATIONS
Another once-daily preparation (SalofalkR granules) also 
proved to be efficacious in inducing remission in mild-
to-moderate active ulcerative colitis in a double-blind, 
randomized, Phase Ⅲ clinical trial, termed SAG-26[27]. 
Three-hundred-eighty patients were randomized to receive 
3 g/d mesalazine granules either once daily (OD) or three 
times per day (TID). At week eight, treatment groups 
achieved comparable clinical (as defined by a CAI ≤ 4 at 
the final/withdrawal visit, 3 g OD: 79.1% vs TID: 75.7%) 
with comparable endoscopic (71% vs 70%) remission and 
histological remission (35% vs 41%) rates. OD treatment 
was more effective in patients with proctosigmoiditis (86% 
vs 73%, P = 0.02), but efficacy was not different according 
to baseline severity and disease duration.
In a combined analysis of  three Phase Ⅲ clinical 
trials (SAG2, SAG15, and SAG26)[28], the efficacy of  
the 3 g/d mesalazine (Salofalk granules) treatment was 
not affected by gender, duration since first symptom, 
disease location or disease duration (new vs established 
disease). In contrast, significantly lower remission rates 
were achieved in patients with moderate disease (66% 
vs 89%; P = 0.0009) and in patients relapsing on 5-ASA 
maintenance therapy (67% vs 82%; P < 0.0001). 
The once-daily maintenance treatment was also 
shown not to be inferior for the mesalazine, 3 g Salofalk 
granules in a double-blind, double-dummy, randomized, 
controlled, dose-ranging study[29]. Six-hundred-forty-
seven patients who have achieved clinical (CAI ≤ 4) 
and endoscopic remission (EI ≤ 3) within 12 wk from 
baseline were randomized to 3 g once daily, 1.5 g once 
daily, and 1.5 g three-times-daily mesalazine treatment. 
At 12 mo, 74.7%, 60.8%, and 68.8% of  patients were 
in clinical remission pointing toward a statistically 
Table 1  Efficacy of the MMX mesalazine formulations for induction and maintenance of remission in mild-to-moderate UC
Study Phase Patient number (n ) Dosing regimen (g/d) Duration Remission rates (%)
Treatment Placebo
Induction 
   D’Haens[14] Ⅱ   38 MMX 1.2   0 
MMX 2.4   8 wk    30.8 -
MMX 4.8 18
   Lichtenstein[15] Ⅲ 280 MMX 2.4   8 wk     34.1a 12.9
MMX 4.8     29.2a
   Kamm[16] Ⅲ 343 MMX 2.4   8 wk     40.5a
MMX 4.8     41.2a 22.1
        Asacol™ 2.4    32.6
   Sandborn[17], [25,26] combined Ⅲ MMX 2.4   8 wk     37.2a 17.5
MMX 4.8     35.1a
Maintenance Patients still in remission
   Kamm[21] Ⅲ 459 MMX 2.4 OD 12 mo 67.8
MMX 2.4 BID 72.3
   Prantera[26] Ⅲ 325 MMX 2.4 OD 12 mo  69.2b
    Asacol™ 2.4 BID 56.8
aP < 0.01 vs placebo; bP < 0.05 between OD vs BID remission rates: Endoscopic and clinical remission rates.
Table 2  Efficacy of other, new mesalazine formulations for induction and maintenance of remission in mild-to-moderate UC
Study Phase Patient number (n ) Dosing regimen (g/d) Duration Remission rates (%) 
Induction 
   Kruis[27] Ⅲ 388 Granules 3 OD   8 wk    79.1%
Granules 3 TID Salofalk®    75.7%
Maintenance Patients still in remission
   Dignass[30] Ⅲ 388 Granules 2 OD 12 mo  73.8a
Granules 2 BID 63.6
Pentasa®
   Kruis[29] Ⅲ 647 Granules 3.0 OD 12 mo 74.7
Granules 1.5 OD 60.8
Granules 1.5 TID 68.8
Salofalk®
aP < 0.05 between OD vs BID.
1802     ISSN 1007-9327     CN 14-1219/R      World J Gastroenterol      April 21, 2009     Volume 15     Number 15
www.wjgnet.com
significant superiority of  the once-daily 3 g treatment 
group. All treatment groups showed excellent safety 
profiles and there were no indications for increased risk 
in patients treated once daily or with the higher dose.
The use of  once-daily treatment for maintenance of  
remission is further supported by a recent randomized, 
multicentre, investigator-blinded study of  362 patients 
who were randomised to receive mesalazine granules 
(PentasaR) 2 g once daily or 1 g twice daily. It showed 
an 11.9% greater remission rate at one year (73.8% vs 
63.6%, respectively) in the single daily dose group[30]. 
The 95% CI values for the treatment difference 
(1.4%-22.5%, P = 0.024) in intent to treat analysis were 
completely above the non-inferiority limit of  -10.0 and 
did not cross 0, therefore once-daily administration of  
the drug proved to be superior to twice-daily treatment. 
Normal mucosa was found in 49.3% and 46.2% of  the 
patients with once-daily or twice-daily treatment and 
there was a trend for less friability in the once-daily 
group (9.7% vs 15.9%). In addition, subjects undergoing 
once-daily treatment had a lower likelihood of  rectal 
bleeding (20.4% vs 29.3%) and also increased rates of  
normal stool frequency (81.5% vs 61.7%) at 12 mo. 
Patient questionnaires showed significantly greater self-
reported compliance (P < 0.05) and acceptability (P < 
0.001) in the once-daily group. High compliance rates 
were reported for the once-daily MMX mesalazine[17], 
therefore the effect is likely to be generic rather than 
compound-specific. The efficacy of  the other new 
mesalazine formulations for the maintenance therapy in 
mild-to-moderate UC is summarized in Table 2.
CONCLUSION
MMX mesalazine and the newly developed mesalazine 
granules were all shown to be efficacious in inducing and 
maintaining remission in mild-to-moderate UC in large 
clinical trials. However, existing data are insufficient to 
make a comparison between new and “conventional” 
5-ASA formulations. Short-term evaluation reveals that 
the new formulations are at least as effective as other 
oral 5-ASA formulations. Recently, MMX mesalazine has 
been approved in the US for the induction of  remission 
in adult patients with active, mild-to-moderate ulcerative 
colitis. In Europe, it is indicated for both induction 
and maintenance of  remission. The safety profile is 
favorable and comparable to that of  other mesalazine 
formulations. In addition, new mesalazine formulations 
offer a simplified dose regime, resulting in presumably 
improved long-term compliance that can be considered 
an important advantage in the management of  UC 
patients. This is of  great importance in everyday clinical 
practice, because only 40% to 60% of  the patients who 
are newly diagnosed or have longstanding disease are 
adherent to therapy. While patients at all stages of  UC 
are affected by non-adherence, those in symptomatic 
remission are particularly at risk of  poor adherence, often 
taking less than 70% of  their prescribed medication, 
with non-adherent patients being more likely to relapse. 
Therefore, improving adherence to therapy has become 
one of  the most important goals of  patient management. 
However, once-daily administration was never tested 
for conventional 5-ASAs. Furthermore, ulcerative colitis 
patients (except proctitis) are at an increased risk for 
colorectal cancer[31,32], and according to a recent meta-
analysis[33], the incidence of  colon cancer is approximately 
50% lower in aminosalicylate users. Thus, improved 
compliance might further contribute to decreasing the 
likelihood of  the colorectal cancer burden in UC. 
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